European Commission clears Bristol-Myers's Sprycel for additional use in newly-diagnosed CML
US drug major Bristol-Myers Squibb (NYSE: BMY) announced yesterday that Sprycel (dasatinib) 100mg once daily received marketing authorization from the European Commission for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP), a rare blood cancer.
A similar approval was recently granted by the US Food and Drug Administration (October 29). The drug generated sales of $144 million (up 35% on the like 2009 period) for B-MS in its current indication in the third quarter of this year (The Pharma Letter October 27). Credit Suisse analysts’ PharmaValues ex-US NPV for Sprycel is $1.75/share or 5.6% net present value for B-MS.
Sprycel has shown superiority to imatinib
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze